Provided by Tiger Trade Technology Pte. Ltd.

Pulmatrix

1.55
+0.05503.68%
Post-market: 1.550.00000.00%16:10 EDT
Volume:16.85K
Turnover:26.04K
Market Cap:5.66M
PE:-1.40
High:1.58
Open:1.43
Low:1.43
Close:1.50
52wk High:5.50
52wk Low:1.16
Shares:3.65M
Float Shares:3.63M
Volume Ratio:0.95
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1034
EPS(LYR):-1.4134
ROE:-98.35%
ROA:-54.69%
PB:3.56
PE(LYR):-1.10

Loading ...

Company Profile

Company Name:
Pulmatrix
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
2
Office Location:
945 Concord Street,Suite 1217,Framingham,Massachusetts,United States
Zip Code:
01701
Fax:
- -
Introduction:
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Directors

Name
Position
Michael J. Higgins
Chairman of the Board and Director
Anand Varadan
Director
Christopher Cabell
Director
Richard Batycky
Director
Todd Bazemore
Director

Shareholders

Name
Position
Peter Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer